MARKET

PHAT

PHAT

Phathom Pharmaceuticals, Inc.
NASDAQ
17.00
+0.72
+4.42%
Opening 10:24 12/19 EST
OPEN
16.39
PREV CLOSE
16.28
HIGH
17.10
LOW
16.39
VOLUME
384.08K
TURNOVER
--
52 WEEK HIGH
17.10
52 WEEK LOW
2.210
MARKET CAP
1.21B
P/E (TTM)
-4.4590
1D
5D
1M
3M
1Y
5Y
1D
Assessing Phathom Pharmaceuticals (PHAT) Valuation After Bullish Rating, Earnings Beat, Raised Guidance and VOQUEZNA Trial Progress
Simply Wall St · 2d ago
Does Earnings Beat And Voquezna Expansion Change The Bull Case For Phathom Pharmaceuticals (PHAT)?
Simply Wall St · 4d ago
Weekly Report: what happened at PHAT last week (1208-1212)?
Weekly Report · 4d ago
Phathom Pharmaceuticals initiated with a Strong Buy at Raymond James
TipRanks · 12/11 21:16
SA Quant ranks meme stocks as GameStop results miss expectations
Seeking Alpha · 12/09 21:52
Phathom Pharmaceuticals Initiated at Equal-Weight by Barclays
Dow Jones · 12/09 16:17
Phathom Pharmaceuticals Price Target Announced at $16.00/Share by Barclays
Dow Jones · 12/09 16:17
PHATHOM PHARMACEUTICALS INC. <PHAT.O>:  BARCLAYS INITIATES COVERAGE WITH EQUAL-WEIGHT RATING AND TARGET PRICE $16
Reuters · 12/09 11:33
More
About PHAT
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s product candidates include VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker, or potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.

Webull offers Phathom Pharmaceuticals Inc stock information, including NASDAQ: PHAT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHAT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PHAT stock methods without spending real money on the virtual paper trading platform.